The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway

(L597V)BRAF mutations are acquired somatically in human cancer samples and are frequently coincident with RAS mutations. Germline (L597V)BRAF mutations are also found in several autosomal dominant developmental conditions known as RASopathies, raising the important question of how the same mutation...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Andreadi, Catherine, Cheung, Lai-Kay, Giblett, Susan, Patel, Bipin, Jin, Hong, Mercer, Kathryn, Kamata, Tamihiro, Lee, Pearl, Williams, Alexander, McMahon, Martin, Marais, Richard, Pritchard, Catrin
Formato: Artigo
Idioma:Inglês
Publicado: Cold Spring Harbor Laboratory Press 2012
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3435497/
https://ncbi.nlm.nih.gov/pubmed/22892241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/gad.193458.112
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares